Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Chlorhexidine→

Chlorhexidine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
55-56-1
Molecular formula
C22H30Cl2N10
Molecular weight
505.4 g/mol
Drug class
Bisbiguanide antiseptictopical membrane-disrupting antimicrobial
Mechanism of action
Interacts with negatively charged microbial cell membranes and cell-wall components, increasing membrane permeability and causing leakage of intracellular contents. At higher concentrations it produces precipitation of cytoplasmic components and cell death.
Indications / reported uses
  • Skin antisepsis and preparation of the skin before invasive procedures using authorised chlorhexidine products
  • Oral rinses for reduction of dental plaque and gingivitis as an adjunct to oral hygiene
  • Selected ophthalmic, wound-care, catheter and device antisepsis applications require route- and concentration-specific products; avoid ocular, middle-ear and neural tissue exposure

Sources: US DailyMed — Chlorhexidine gluconate products · NHS — Chlorhexidine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Chlorhexidine Environmental Risk Assessment (ERA) (the Chlorhexidine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.